• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Hepatobiliary Surgery and Nutrition >Perspectives on using des-γ-carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in China
【2h】

Perspectives on using des-γ-carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in China

机译：使用des-γ-羧基凝血酶原（DCP）作为血清生物标志物的观点：促进中国肝细胞癌的早期发现

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths in China. Evidence has shown that surgical resection and liver transplantation may offer the best potential for treating HCC but are only available to patients whose tumors are detected early. Over the past few decades, although a series of measures for standardized management of HCC has been implemented in China, most patients with HCC in China still present with advanced-stage disease, thus strategies to screen for and diagnose HCC at an earlier stage are urgently needed in China when curable interventions can be offered to achieve long-term disease-free survival for patients with HCC. In China, the serum biomarker α-fetoprotein (AFP) is considered a useful and feasible tool for HCC screening and early diagnosis. However, the sensitivity and specificity of AFP vary widely, and the total AFP is not always specific, especially when HCC is in its early stages. Globally, numerous studies have reported that the combination of des-γ-carboxyprothrombin (DCP) and AFP may have a higher sensitivity than AFP alone, and suggested DCP could also be used to assess the progression of HCC. However, DCP has not been approved in China until now. Differ from most of Western countries, people with HBV infection are the largest population at risk of developing HCC China. In order to assess the screening and diagnostic value of DCP in Chinese patients with HCC, a first large-scale, multi-center study was launched in China in 2012, results showed that DCP can help to detect HCC in its early stages and facilitate definitive treatment. The clinical use of DCP is urgently needed to facilitate early detection of HCC in China.
机译：肝细胞癌（HCC）是中国癌症相关死亡的第二大主要原因。有证据表明，手术切除和肝移植可能是治疗HCC的最佳潜力，但仅对早期发现肿瘤的患者有效。在过去的几十年中，尽管在中国已经实施了一系列的HCC标准化管理措施，但是中国的大多数HCC患者仍然患有晚期疾病，因此迫切需要在早期阶段筛查和诊断HCC的策略。当可以提供可治愈的干预措施以实现HCC患者的长期无病生存时，这是中国所需要的。在中国，血清生物标志物甲胎蛋白（AFP）被认为是用于HCC筛查和早期诊断的有用且可行的工具。但是，AFP的敏感性和特异性相差很大，总的AFP并非总是特异性的，尤其是在肝癌处于早期阶段时。在全球范围内，许多研究报告称，去-γ-羧基凝血酶原（DCP）和AFP的联合使用可能比单独使用AFP的敏感性更高，并且建议DCP也可以用于评估HCC的进展。但是，到目前为止，DCP在中国尚未获得批准。与大多数西方国家不同，乙肝病毒感染者是发展中国肝癌的最大风险人群。为了评估DCP在中国HCC患者中的筛查和诊断价值，2012年在中国启动了第一项大规模，多中心研究，结果表明DCP可以帮助早期检测HCC并有助于确定性治疗。在中国，迫切需要DCP的临床使用以促进HCC的早期发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号